4 Joint International Patents: Cancer, Pain, Vaccine, IBS
Nov 22, 2015 11:12:25 GMT -5
via mobile
otherottawaguy, ezrasfund, and 8 more like this
Post by lakers on Nov 22, 2015 11:12:25 GMT -5
I, CANCER
Application Number: 14431476 Application Date: 25.09.2013
Publication Number: 20150266870 Publication Date: 24.09.2015
Applicants: MANNKIND CORPORATION TOLERO PHARMACEUTICALS, INC
Title: MULTIPLE KINASE PATHWAY INHIBITORS
II. PAIN
Application Number: 14622660 Application Date: 13.02.2015
Publication Number: 20150150980 Publication Date: 04.06.2015
Applicants: MannKind Corporation Torrey Pines Institute for Molecular Studies
Title: METHODS AND COMPOSITIONS FOR TREATING PAIN
register.epo.org/application?number=EP12784825&tab=main
www.google.com.ar/patents/US20150150980
III. VACCINE
Pub. No.: WO/2014/066856 International Application Nhttps://register.epo.org/application?number=EP12784825&tab=maino.: PCT/US2013/066969
Publication Date: 01.05.2014 International Filing Date: 25.10.2013
Applicants: MANNKIND CORPORATION TECHNOVAX, INC.
Title INHALABLE INFLUENZA VACCINE COMPOSITIONS AND METHODS
IV. IRRITABLE BOWEL SYNDROME
Application Number: 14139714 Application Date: 23.12.2013
Publication Number: 20140187490 Publication Date: 03.07.2014
Applicants: Rose Pharma A/S MannKind Corporation
Title: Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
V. DIABETES
Mannkind has an Inhaled Technosphere GLP-1 Drug Candiate tested in Phase II Trial targeting the treatment of Diabetes, which Sanofi has the right of first refusal to sign a joint development agreement if they choose.
patents.justia.com/search?q=Mannkind+Glp
finance.yahoo.com/mbview/searchview/?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&q=method%20and%20composition%20for%20treating%20pain&in=b&sm=
Stability of Novel Pain Therapy Tetrapeptide TPI-23 in Technosphere® Inhalation Powder and
Identification of Related-Compounds by Liquid Chromatography/Mass Spectrometry
Y. Livson, E. Harris, K. Fabio, J. Guarneri
MannKind Corporation
Read more: mnkd.proboards.com/thread/3694/flolan-migrained-imitrex-antiematic-zofran?page=4#ixzz3sEnCQ0Lw
VI. Latest EU Pain Patent 11/20/15 in German, French, English
Mnkd is telegraphing that they are negotiating with a Pain/Migraine partner. Note the new headquarter address.
In May 2015, Matt said Mnkd might pay off $100M Notes in Cash. Somehow the deal must have dragged longer than expected. You can deduce that the upfront licensing cash is at least $150M. Unlike Sanofi deal it can be booked as rev immediately and spent right away.
Status Examination is in progress
Database last updated on 20.11.2015
First examination report published on 23.12.2015 [2015/52]
Applicant(s) For all designated states
MannKind Corporation
25134 Rye Canyon Loop
Valencia CA 91355 / US
For all designated states
Torrey Pines Institute for Molecular Studies
11350 SW Village Parkway
Port St. Lucie, FL 34987 / US
[N/P]
Inventor(s) 01 / LEONE-BAY, Andrea
297 Florida Hill Road
Ridgefield, CT 06877 / US
02 / HOUGHTEN, Richard, A.
295 Riverway Drive
Vero Beach, FL 32963-2645 / US
03 / GUARNERI, Joseph, J.
72 Geriak Road
Stamford, CT 06905 / US
04 / STOWELL, Grayson, W.
213 Lost Tree Lane
Cary, NC 27513 / US
[2014/43]
Representative(s) Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham, NG1 5GG / GB
[2014/38]
Application number, filing date 12784825.7 24.10.2012
WO2012US61749
Priority number, date US201161550860P 24.10.2011 Original published format: US 201161550860 P
[2014/38]
Filing language EN
Procedural language EN
Publication Type: A1 Application with search report
No.: WO2013063160
Date: 02.05.2013
Language: EN
[2013/18]
Type: A1 Application with search report
No.: EP2776053
Date: 17.09.2014
Language: EN
The application has been published by WIPO in one of the EPO official languages on 02.05.2013
[2014/38]
International and Supplementary
search report(s) International search report -
published on: EP 02.05.2013
Classification International: A61K38/04, A61K38/07, A61K38/08, A61K9/00
[2014/38]
Designated contracting states AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/38]
Title German: VERFAHREN UND ZUSAMMENSETZUNGEN ZUR SCHMERZBEHANDLUNG [2014/38]
English: METHODS AND COMPOSITIONS FOR TREATING PAIN [2014/38]
French: PROCÉDÉS ET COMPOSITIONS POUR TRAITER LA DOULEUR [2014/38]
Entry into regional phase 23.04.2014 National basic fee paid
23.04.2014 Designation fee(s) paid
23.04.2014 Examination fee paid
Examination procedure 23.04.2014 Examination requested [2014/38]
12.01.2015 Amendment by applicant (claims and/or description)
24.11.2015 Despatch of a communication from the examining division (Time limit: M04)
Divisional application(s) The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.11.2015
Fees paid Renewal fee
27.10.2014 Renewal fee patent year 03
27.10.2015 Renewal fee patent year 04
Cited in International search [XY]WO2010144789
XP002692814 A 00000000 [ ]
[Y]EP2314298
[Y]WO9640206
[Y]WO9627386
[Y]WO9932510
WO2010125103
ROSÉN ANNIKA ET AL, "Substance P microinjected into the periaqueductal gray matter induces antinociception and is released following morphine administration.", BRAIN RESEARCH 19 MAR 2004, (20040319), vol. 1001, no. 1-2, ISSN 0006-8993, PAGE 87 - 94, XP002692813 1-17 See abstract: Substance P induces antinociceptic response
DOI: dx.doi.org/10.1016/J.BRAINRES.2003.11.060
YAN G P ET AL, "[Analgesic action of microinjection of neurokinin A into the lateral reticular nucleus and nucleus raphe magnus in rats].", DATABASE MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, Database accession no. NLM9387783, XP002692814 1-17 See the abstract: Neurokinin A has analgesic effect
[ ] YAN G P ET AL, "[Analgesic action of microinjection of neurokinin A into the lateral reticular nucleus and nucleus raphe magnus in rats].", SHENG LI XUE BAO : [ACTA PHYSIOLOGICA SINICA] OCT 1996, (199610), vol. 48, no. 5, ISSN 0371-0874, PAGE 493 - 496, XP002692814
By applicant:
US5610271
US5352461
US5503852
US6071497
US6331318
US7820676
US6428771
US7799344
US7803404
US6703381
US7804404
US2009308390
US2009308391
US2010197565
US2009308392
US2010238457
Application Number: 14431476 Application Date: 25.09.2013
Publication Number: 20150266870 Publication Date: 24.09.2015
Applicants: MANNKIND CORPORATION TOLERO PHARMACEUTICALS, INC
Title: MULTIPLE KINASE PATHWAY INHIBITORS
II. PAIN
Application Number: 14622660 Application Date: 13.02.2015
Publication Number: 20150150980 Publication Date: 04.06.2015
Applicants: MannKind Corporation Torrey Pines Institute for Molecular Studies
Title: METHODS AND COMPOSITIONS FOR TREATING PAIN
register.epo.org/application?number=EP12784825&tab=main
www.google.com.ar/patents/US20150150980
III. VACCINE
Pub. No.: WO/2014/066856 International Application Nhttps://register.epo.org/application?number=EP12784825&tab=maino.: PCT/US2013/066969
Publication Date: 01.05.2014 International Filing Date: 25.10.2013
Applicants: MANNKIND CORPORATION TECHNOVAX, INC.
Title INHALABLE INFLUENZA VACCINE COMPOSITIONS AND METHODS
IV. IRRITABLE BOWEL SYNDROME
Application Number: 14139714 Application Date: 23.12.2013
Publication Number: 20140187490 Publication Date: 03.07.2014
Applicants: Rose Pharma A/S MannKind Corporation
Title: Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
V. DIABETES
Mannkind has an Inhaled Technosphere GLP-1 Drug Candiate tested in Phase II Trial targeting the treatment of Diabetes, which Sanofi has the right of first refusal to sign a joint development agreement if they choose.
patents.justia.com/search?q=Mannkind+Glp
finance.yahoo.com/mbview/searchview/?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&q=method%20and%20composition%20for%20treating%20pain&in=b&sm=
Stability of Novel Pain Therapy Tetrapeptide TPI-23 in Technosphere® Inhalation Powder and
Identification of Related-Compounds by Liquid Chromatography/Mass Spectrometry
Y. Livson, E. Harris, K. Fabio, J. Guarneri
MannKind Corporation
Read more: mnkd.proboards.com/thread/3694/flolan-migrained-imitrex-antiematic-zofran?page=4#ixzz3sEnCQ0Lw
VI. Latest EU Pain Patent 11/20/15 in German, French, English
Mnkd is telegraphing that they are negotiating with a Pain/Migraine partner. Note the new headquarter address.
In May 2015, Matt said Mnkd might pay off $100M Notes in Cash. Somehow the deal must have dragged longer than expected. You can deduce that the upfront licensing cash is at least $150M. Unlike Sanofi deal it can be booked as rev immediately and spent right away.
Status Examination is in progress
Database last updated on 20.11.2015
First examination report published on 23.12.2015 [2015/52]
Applicant(s) For all designated states
MannKind Corporation
25134 Rye Canyon Loop
Valencia CA 91355 / US
For all designated states
Torrey Pines Institute for Molecular Studies
11350 SW Village Parkway
Port St. Lucie, FL 34987 / US
[N/P]
Inventor(s) 01 / LEONE-BAY, Andrea
297 Florida Hill Road
Ridgefield, CT 06877 / US
02 / HOUGHTEN, Richard, A.
295 Riverway Drive
Vero Beach, FL 32963-2645 / US
03 / GUARNERI, Joseph, J.
72 Geriak Road
Stamford, CT 06905 / US
04 / STOWELL, Grayson, W.
213 Lost Tree Lane
Cary, NC 27513 / US
[2014/43]
Representative(s) Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham, NG1 5GG / GB
[2014/38]
Application number, filing date 12784825.7 24.10.2012
WO2012US61749
Priority number, date US201161550860P 24.10.2011 Original published format: US 201161550860 P
[2014/38]
Filing language EN
Procedural language EN
Publication Type: A1 Application with search report
No.: WO2013063160
Date: 02.05.2013
Language: EN
[2013/18]
Type: A1 Application with search report
No.: EP2776053
Date: 17.09.2014
Language: EN
The application has been published by WIPO in one of the EPO official languages on 02.05.2013
[2014/38]
International and Supplementary
search report(s) International search report -
published on: EP 02.05.2013
Classification International: A61K38/04, A61K38/07, A61K38/08, A61K9/00
[2014/38]
Designated contracting states AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/38]
Title German: VERFAHREN UND ZUSAMMENSETZUNGEN ZUR SCHMERZBEHANDLUNG [2014/38]
English: METHODS AND COMPOSITIONS FOR TREATING PAIN [2014/38]
French: PROCÉDÉS ET COMPOSITIONS POUR TRAITER LA DOULEUR [2014/38]
Entry into regional phase 23.04.2014 National basic fee paid
23.04.2014 Designation fee(s) paid
23.04.2014 Examination fee paid
Examination procedure 23.04.2014 Examination requested [2014/38]
12.01.2015 Amendment by applicant (claims and/or description)
24.11.2015 Despatch of a communication from the examining division (Time limit: M04)
Divisional application(s) The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.11.2015
Fees paid Renewal fee
27.10.2014 Renewal fee patent year 03
27.10.2015 Renewal fee patent year 04
Cited in International search [XY]WO2010144789
XP002692814 A 00000000 [ ]
[Y]EP2314298
[Y]WO9640206
[Y]WO9627386
[Y]WO9932510
WO2010125103
ROSÉN ANNIKA ET AL, "Substance P microinjected into the periaqueductal gray matter induces antinociception and is released following morphine administration.", BRAIN RESEARCH 19 MAR 2004, (20040319), vol. 1001, no. 1-2, ISSN 0006-8993, PAGE 87 - 94, XP002692813 1-17 See abstract: Substance P induces antinociceptic response
DOI: dx.doi.org/10.1016/J.BRAINRES.2003.11.060
YAN G P ET AL, "[Analgesic action of microinjection of neurokinin A into the lateral reticular nucleus and nucleus raphe magnus in rats].", DATABASE MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, Database accession no. NLM9387783, XP002692814 1-17 See the abstract: Neurokinin A has analgesic effect
[ ] YAN G P ET AL, "[Analgesic action of microinjection of neurokinin A into the lateral reticular nucleus and nucleus raphe magnus in rats].", SHENG LI XUE BAO : [ACTA PHYSIOLOGICA SINICA] OCT 1996, (199610), vol. 48, no. 5, ISSN 0371-0874, PAGE 493 - 496, XP002692814
By applicant:
US5610271
US5352461
US5503852
US6071497
US6331318
US7820676
US6428771
US7799344
US7803404
US6703381
US7804404
US2009308390
US2009308391
US2010197565
US2009308392
US2010238457